Intellia Therapeutics, Inc.
NTLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -3.3% | -14.3% | 29.2% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -472.8% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -699.4% | -754.8% | -711.5% | -1,039.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -735.2% | -710.8% | -687.6% | -1,001.2% |
| EPS Diluted | -0.92 | -0.98 | -1.1 | -1.27 |
| % Growth | 6.1% | 10.9% | 13.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |